search
Back to results

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Primary Purpose

COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
RQ-001
Placebo
Sponsored by
Red Queen Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID-19 focused on measuring First in Human, Phase 1, COVID, Telemedicine

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18-64, inclusive, at the time of consent. Have mild COVID-19 disease symptom(s) at screening and at randomization, as defined in the protocol. Female subjects must have a negative urine pregnancy test at screening. Females of childbearing potential must agree to abstain from heterosexual intercourse or use highly effective contraception, as defined in the protocol. Male subjects must agree to abstain from heterosexual intercourse or use double barrier protection with condom and spermicide with any sexual partner who has the capacity for pregnancy and agree to not donate sperm. Understand the risks of the trial and consents to study conduct documented by signing of the study informed consent form. Willing and able to comply with this protocol and be available for the entire duration of the study. Exclusion Criteria: Moderate or severe COVID-19 disease at the time of screening, including but not limited to displaying one or more of the following clinical symptoms outlined in the protocol Individuals who are eligible for FDA authorized or approved COVID-19 therapeutics (e.g., antivirals or monoclonal antibodies) Subjects at high-risk for COVID-19 disease severity progression at the time of screening, defined as subjects with known history or current diagnoses of any of the following conditions outlined in the protocol. Sinusitis ongoing for more than 4 weeks at the time of screening. Clinically significant epistaxis, as determined by the Investigator, within 3 months prior to screening. Nasal or sinus surgery within 12 weeks prior to screening, planned to occur during the study, or a history of any nasal or sinus surgery that in the opinion of the Investigator may influence COVID-19 disease symptoms or spray administration of the study drug. Nasal polyps or other non-infectious condition that could cause nasal obstruction, such as severe nasal septal deviation. Use of intranasal, inhaled, or oral corticosteroid medications of any kind within 14 days prior to the first dose of study drug, or planned use during the study that may affect the administration and/or absorption of study drug. Note: The use of oral antihistamines is permitted during the study. Use of antivirals or monoclonal antibodies for the management of COVID-19 disease or other viruses (e.g., influenza) within 60 days prior to the first dose of study drug. Received a vaccination for COVID-19 disease (original series or boosters) within 30 days prior to the first dose of study drug, and/or has plans to receive a COVID-19 vaccination (original series or boosters) during the trial through Day 33. Note: Other vaccinations are permitted during the trial through Day 33 and must be reported as a concomitant treatment. Have known systemic hypersensitivity to the RQ-01 drug substance, its inactive ingredients, or the ingredients of the matching placebo. For female subjects, are pregnant or breastfeeding, are < 1 month post-partum or are planning to become pregnant during the study. Have any condition that, in the opinion of the Investigator, would interfere with evaluation of the study drug or interpretation of the subject's safety or study results. Unwilling to abstain from participating in another interventional clinical study with an investigational compound or device, including SARS-CoV-2 therapeutics.

Sites / Locations

  • LA Universal Research Center, Inc.
  • AGA Clinical Trials - Hypercore - PPDS
  • Florida International Medical ResearchRecruiting
  • University of Maryland School of Medicine
  • Prime Global Research, Inc.
  • Zenos Clinical ResearchRecruiting
  • Vilo Research Group, L.L.C.
  • Zion Urgent Care Clinic
  • Evergreen Hospital Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Low Dose of RQ-01

High Dose of RQ-01

Placebo

Arm Description

Subjects in this arm will receive 5 mg per day (for 3 days) of RQ-01

Subjects in this arm will receive 10 mg per day (for 3 days) of RQ-01

Subjects in this arm will receive 0 mg per day (for 3 days) of RQ-01

Outcomes

Primary Outcome Measures

Incidence of TEAEs
The difference between treatment arms in the incidence of treatment-emergent adverse events (TEAEs) leading to withdrawal of study drug or study discontinuation through Day 33/End of Study.
Change in clinical laboratory results
The difference between treatment arms in the change from baseline in clinical laboratory results.
Change in physical examination results
The difference between treatment arms in the change from baseline in physical examination results.
Change in vital signs
The difference between treatment arms in the change from baseline in vital signs.

Secondary Outcome Measures

Change in SARS-CoV-2 RNA shedding
The difference between treatment arms in the time-weighted average change in log10 SARS-CoV-2 SARS-CoV-2 RNA shedding from Baseline (Day 1) through Day 33 as measured by RT-qPCR.
Proportion of subjects with undetectable SARS-CoV-2 RNA shedding
The difference between treatment arms in the proportion of subjects with undetectable SARS-CoV-2 RNA shedding as measured by RT-qPCR by visit.
Change in SARS-CoV-2 RNA shedding
The difference in the change from baseline to Day 5 between treatment arms in the AUC SARS-CoV-2 RNA shedding as measured by RT-qPCR.
Proportion of subjects with negative RT-qPCR
The difference between treatment arms in the proportion of subjects with negative RT-qPCR through Day 33.
Time to negative RT-qPCR
The difference between treatment arms in the time to negative RT-qPCR.
Proportion of rebounds
The difference between treatment arms in the proportion of rebounds (defined as: viral RNA ≥lower limit of quantitation (LLOQ) after Day 5 if <LLOQ at Day 5, or ≥1 log10 increase in viral RNA copy number (relative to Day 5) after Day 5 if ≥LLOQ at Day 5.
Proportion of subjects using additional therapeutic alternatives
The difference in proportion between treatment arms of subjects who used additional therapeutic alternatives for the management COVID-19 disease (as recommended by the National Institutes of Health [NIH]) for non-hospitalized COVID-19 subjects by treatment arms through Day 33.
Proportion of subjects with no symptoms
The difference in proportion between treatment arms of subjects with no symptoms through Day 33 as measured by the 15 items COVID-19 Symptoms Score.
Mean change in symptoms
The difference in the mean change from baseline through Day 33 as measured by the 15 items COVID-19 Symptoms Score.

Full Information

First Posted
September 17, 2023
Last Updated
October 10, 2023
Sponsor
Red Queen Therapeutics, Inc.
Collaborators
PPD
search

1. Study Identification

Unique Protocol Identification Number
NCT06063330
Brief Title
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
Official Title
A Phase 1, Multicenter, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 27, 2023 (Actual)
Primary Completion Date
February 16, 2024 (Anticipated)
Study Completion Date
February 16, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Red Queen Therapeutics, Inc.
Collaborators
PPD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a first in human clinical study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RQ-01. Adult patients who have tested positive for SARS-CoV-2 virus, have mild symptom(s) of COVID-19 disease, and who are at low risk for developing moderate or severe COVID-19 disease are welcome to participate. The main questions this study aims to answer are: What is the safety profile of RQ-01? What is the reduction in SARS-CoV-2 ribonucleic acid (RNA) shedding after administration of RQ-01? How effective is RQ-01 versus placebo in reducing COVID-19 symptoms? After providing informed consent, subjects will be randomized to RQ-01 (high or low dose) or placebo and will be dosed for 3 consecutive days. Throughout the duration of the trial, subjects will participate in the following activities: perform rapid antigen and polymerase chain reaction (PCR) tests for COVID-19, answer questions about their medical history and medications, answer questions about their COVID-19 history and symptoms, conduct a physical exam, have their vitals measured, and have bloodwork done.
Detailed Description
This is a first in human study to evaluate the safety, PK, and PD of RQ-01 when administered to adult subjects who have tested positive for SARS-CoV-2 virus, have mild symptom(s) of COVID-19 disease, and who are at low risk for developing moderate or severe COVID-19 disease. Subjects will be exposed to RQ-01 after nasal administration with the Aptar Bidose nasal spray device (BDSI V3). The decrease in SARS-CoV-2 RNA shedding will be measured by reverse transcription-quantitative polymerase chain reaction (RT- qPCR) compared with placebo. There are currently no Food and Drug Administration (FDA) approved therapies for subjects with mild symptoms of COVID who are low risk for progression to moderate-severe disease. Safety of the subjects in this study is supported by the safety margin for local adverse events, lack of systemic exposure, and availability of antiviral therapies for COVID-19 should subjects' disease progress. The study may be conducted using traditional outpatient clinic sites or a hybrid model, using clinic sites and/or virtual sites, with provisions made to conduct aspects of the study via telehealth and/or within subjects' homes. The hybrid model will provide the flexibility required to offer the trial in areas with increased incidence of COVID-19 disease, to maximize access to trial participation, and to increase diversity of trial subjects. Potential study subjects will be identified for screening based on having at least one mild symptom consistent with COVID-19 disease. Potential study subjects may additionally present with a positive SARS-CoV-2 rapid antigen test (RAT), taken either at-home, or administered at a facility (e.g., urgent care testing site). As detailed within the inclusion criteria, different entry requirements apply depending on the source and timing of the positive rapid antigen test. For all subjects, the time from first positive SARS-CoV-2 rapid antigen test result to time of first dose must not exceed 3 days. Also, the first dose of study drug must be administered within 4 days of the estimated initial onset of symptoms of COVID-19 disease. Subjects who provide written informed consent and meet all eligibility criteria will be randomized in a 1:1:1 manner to RQ-01 (high or low dose) or placebo. On the day of randomization, all subjects must have at least one mild symptom of COVID-19 disease and a positive SARS-CoV-2 RAT result. After the first six subjects are enrolled (2 in each group) and have completed all study procedures through Day 7 an early interim safety analysis will be performed by the Data Monitoring Committee. Enrollment of new subjects will continue only after review by the Data Monitoring Committee and the decision to proceed communicated to the investigators. Prior to the first dose of study drug, all subjects must be trained by study staff on study drug self-administration with the Aptar Bidose nasal spray device, per the instructions provided within the Pharmacy Manual and/or subject-facing materials. Subjects will self-administer all doses of study drug while observed in-person by the Investigator or designee, who must be a trained healthcare professional. Subjects will then be followed for an additional 30 days for overall safety including COVID-19 disease symptoms. If at any point during the study a subject meets the treatment discontinuation criteria outlined within the protocol, including a worsening of COVID-19 disease symptoms, the subject will be immediately discontinued from study drug and will continue in follow-up as described within the protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
Keywords
First in Human, Phase 1, COVID, Telemedicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
There are 3 different treatment arms that subjects will be randomized in a 1:1:1 ratio. The arms will be evenly distributed with 22 subjects in each arm: 1) low dose of RQ-01; 2) high dose of RQ-01; 3) Placebo
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
66 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low Dose of RQ-01
Arm Type
Experimental
Arm Description
Subjects in this arm will receive 5 mg per day (for 3 days) of RQ-01
Arm Title
High Dose of RQ-01
Arm Type
Experimental
Arm Description
Subjects in this arm will receive 10 mg per day (for 3 days) of RQ-01
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects in this arm will receive 0 mg per day (for 3 days) of RQ-01
Intervention Type
Combination Product
Intervention Name(s)
RQ-001
Intervention Description
Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components. Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
Primary Outcome Measure Information:
Title
Incidence of TEAEs
Description
The difference between treatment arms in the incidence of treatment-emergent adverse events (TEAEs) leading to withdrawal of study drug or study discontinuation through Day 33/End of Study.
Time Frame
Through 33 days
Title
Change in clinical laboratory results
Description
The difference between treatment arms in the change from baseline in clinical laboratory results.
Time Frame
Through 33 days
Title
Change in physical examination results
Description
The difference between treatment arms in the change from baseline in physical examination results.
Time Frame
Up to 33 days
Title
Change in vital signs
Description
The difference between treatment arms in the change from baseline in vital signs.
Time Frame
Up to 33 days
Secondary Outcome Measure Information:
Title
Change in SARS-CoV-2 RNA shedding
Description
The difference between treatment arms in the time-weighted average change in log10 SARS-CoV-2 SARS-CoV-2 RNA shedding from Baseline (Day 1) through Day 33 as measured by RT-qPCR.
Time Frame
Through 33 days
Title
Proportion of subjects with undetectable SARS-CoV-2 RNA shedding
Description
The difference between treatment arms in the proportion of subjects with undetectable SARS-CoV-2 RNA shedding as measured by RT-qPCR by visit.
Time Frame
Up to 33 days
Title
Change in SARS-CoV-2 RNA shedding
Description
The difference in the change from baseline to Day 5 between treatment arms in the AUC SARS-CoV-2 RNA shedding as measured by RT-qPCR.
Time Frame
Up to 5 days
Title
Proportion of subjects with negative RT-qPCR
Description
The difference between treatment arms in the proportion of subjects with negative RT-qPCR through Day 33.
Time Frame
Through 33 days
Title
Time to negative RT-qPCR
Description
The difference between treatment arms in the time to negative RT-qPCR.
Time Frame
Up to 33 days
Title
Proportion of rebounds
Description
The difference between treatment arms in the proportion of rebounds (defined as: viral RNA ≥lower limit of quantitation (LLOQ) after Day 5 if <LLOQ at Day 5, or ≥1 log10 increase in viral RNA copy number (relative to Day 5) after Day 5 if ≥LLOQ at Day 5.
Time Frame
Through 33 days
Title
Proportion of subjects using additional therapeutic alternatives
Description
The difference in proportion between treatment arms of subjects who used additional therapeutic alternatives for the management COVID-19 disease (as recommended by the National Institutes of Health [NIH]) for non-hospitalized COVID-19 subjects by treatment arms through Day 33.
Time Frame
Through 33 days
Title
Proportion of subjects with no symptoms
Description
The difference in proportion between treatment arms of subjects with no symptoms through Day 33 as measured by the 15 items COVID-19 Symptoms Score.
Time Frame
Through 33 days
Title
Mean change in symptoms
Description
The difference in the mean change from baseline through Day 33 as measured by the 15 items COVID-19 Symptoms Score.
Time Frame
Through 33 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-64, inclusive, at the time of consent. Have mild COVID-19 disease symptom(s) at screening and at randomization, as defined in the protocol. Female subjects must have a negative urine pregnancy test at screening. Females of childbearing potential must agree to abstain from heterosexual intercourse or use highly effective contraception, as defined in the protocol. Male subjects must agree to abstain from heterosexual intercourse or use double barrier protection with condom and spermicide with any sexual partner who has the capacity for pregnancy and agree to not donate sperm. Understand the risks of the trial and consents to study conduct documented by signing of the study informed consent form. Willing and able to comply with this protocol and be available for the entire duration of the study. Exclusion Criteria: Moderate or severe COVID-19 disease at the time of screening, including but not limited to displaying one or more of the following clinical symptoms outlined in the protocol Individuals who are eligible for FDA authorized or approved COVID-19 therapeutics (e.g., antivirals or monoclonal antibodies) Subjects at high-risk for COVID-19 disease severity progression at the time of screening, defined as subjects with known history or current diagnoses of any of the following conditions outlined in the protocol. Sinusitis ongoing for more than 4 weeks at the time of screening. Clinically significant epistaxis, as determined by the Investigator, within 3 months prior to screening. Nasal or sinus surgery within 12 weeks prior to screening, planned to occur during the study, or a history of any nasal or sinus surgery that in the opinion of the Investigator may influence COVID-19 disease symptoms or spray administration of the study drug. Nasal polyps or other non-infectious condition that could cause nasal obstruction, such as severe nasal septal deviation. Use of intranasal, inhaled, or oral corticosteroid medications of any kind within 14 days prior to the first dose of study drug, or planned use during the study that may affect the administration and/or absorption of study drug. Note: The use of oral antihistamines is permitted during the study. Use of antivirals or monoclonal antibodies for the management of COVID-19 disease or other viruses (e.g., influenza) within 60 days prior to the first dose of study drug. Received a vaccination for COVID-19 disease (original series or boosters) within 30 days prior to the first dose of study drug, and/or has plans to receive a COVID-19 vaccination (original series or boosters) during the trial through Day 33. Note: Other vaccinations are permitted during the trial through Day 33 and must be reported as a concomitant treatment. Have known systemic hypersensitivity to the RQ-01 drug substance, its inactive ingredients, or the ingredients of the matching placebo. For female subjects, are pregnant or breastfeeding, are < 1 month post-partum or are planning to become pregnant during the study. Have any condition that, in the opinion of the Investigator, would interfere with evaluation of the study drug or interpretation of the subject's safety or study results. Unwilling to abstain from participating in another interventional clinical study with an investigational compound or device, including SARS-CoV-2 therapeutics.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kristin Kenaston, MBA
Phone
617-433-1699
Email
kkenaston@redqueentx.com
Facility Information:
Facility Name
LA Universal Research Center, Inc.
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Torkan
Phone
213-359-9091
Email
investigator1@launiresearch.com
Facility Name
AGA Clinical Trials - Hypercore - PPDS
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wilson Cueva
Email
wcueva@agaclinicaltrials.com
Facility Name
Florida International Medical Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roberto Garcia Ramirez
Phone
855-500-3467
Email
rgarcia.fimresearch@gmail.com
Facility Name
University of Maryland School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shyamasundaran Kottilil
Phone
410-706-8927
Email
skottilil@ihv.umaryland.edu
Facility Name
Prime Global Research, Inc.
City
Bronx
State/Province
New York
ZIP/Postal Code
10456
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rubaba (Ruby) Hussain
Phone
718-530-0051
Email
rubie@outlook.com
Facility Name
Zenos Clinical Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Lilly
Phone
256-708-2826
Email
quinnmd@cullmanclinicaltrials.com
Facility Name
Vilo Research Group, L.L.C.
City
Houston
State/Province
Texas
ZIP/Postal Code
77017
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luis Zepeda
Phone
713-634-0200
Email
zepedamd@viloresearchgroup.com
Facility Name
Zion Urgent Care Clinic
City
Katy
State/Province
Texas
ZIP/Postal Code
77494
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tewodros Teketel
Phone
832-224-5202
Facility Name
Evergreen Hospital Medical Center
City
Kirkland
State/Province
Washington
ZIP/Postal Code
98034
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chad Crystal
Phone
425-650-0019
Email
ccrystal@eastsideresearch.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

We'll reach out to this number within 24 hrs